On April 12, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that Dr. Sebastian Chung from Memorial Sloan Kettering Cancer Center ("MSK") presented a virtual poster discussing the SADA technology platform for pre-targeted radioimmunotherapy against GPA33 in a xenograft model of colorectal peritoneal carcinomatosis at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting on April 10, 2021 (Press release, Y-mAbs Therapeutics, APR 12, 2021, View Source [SID1234577900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SADA technology utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs to radiate the tumor. Y-mAbs expects to submit its first IND for a SADA construct targeting GD2 in the fourth quarter of 2021.

The GPA33-SADA construct was created using the SADA technology, which was licensed by the Company from MSK and Massachusetts Institute of Technology ("MIT") in April 2020. In a xenograft model of colorectal peritoneal carcinomatosis, GPA33-SADA showed a favorable tumor to blood ratio radioactivity uptake of 122 measured 24 hours after injection. GPA33 is expressed on 95% of all colorectal cancers. An IND for the GPA33-SADA is targeted for next year.

Researchers at MSK developed GPA33-SADA, which is exclusively licensed by MSK and MIT to Y-mAbs. As a result of this licensing arrangement, both MSK and MIT have institutional financial interests related to the compound and Y-mAbs.